Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-CATALIS: Immunotherapy and Induction Chemotherapy in dMMR/MSI-H Gastric/GEJ Adenocarcinoma
NCT07259473Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2026
- Primary completion
- Dec 2029
01
Overview
Phase 2, open-label, single-arm trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Pathological Complete Response Rate at 14 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07259473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259473.